Telesis Bio INC 8-K filings

Telesis Bio Inc. has entered into promissory notes with Novalis LifeSciences Investments II, L.P. and Northpond Ventures III, LP, securing $3 million in debt financing.

Telesis Bio Inc. has announced the departure of its Chief Legal Officer, Robert H. Cutler, effective October 31, 2024, and detailed the terms of his separation agreement.

Telesis Bio has announced its decision to delist from the Nasdaq Global Select Market due to its inability to meet minimum listing requirements.

Telesis Bio Inc. reports the immediate resignation of five board members and subsequent appointment of new committee members, including the CEO as board chair.

Telesis Bio Inc. has finalized the sale of its wholly-owned subsidiary, EtonBio, Inc., to Yuan (Terry) Yang, as of August 26, 2024.

Telesis Bio Inc. has agreed to sell its wholly-owned subsidiary, Eton Bio, Inc., to Yuan (Terry) Yang for $1.5 million, pending customary closing conditions.

Telesis Bio reported a significant decrease in revenue for the second quarter of 2024, alongside restructuring efforts and a strategic divestiture.

Telesis Bio has obtained $5.85 million in financing through promissory notes, leading to a significant restructuring of its board of directors.

Telesis Bio Inc. has received a notification from Nasdaq that its Market Value of Publicly Held Shares (MVPHS) has fallen below the required minimum, placing it at risk of delisting.

Telesis Bio's first quarter 2024 results show a decrease in revenue compared to the same period last year, but also a significant reduction in operating expenses.

Telesis Bio has announced a 1-for-18 reverse stock split of its common stock, effective May 9, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Telesis Bio is focusing on its Gibson SOLA enzymatic DNA synthesis platform and BioXp mRNA solutions, while also announcing a change in CEO.

Telesis Bio Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement and has until May 20, 2024, to submit a compliance plan.

Telesis Bio announced its fourth quarter and full year 2023 financial results, highlighting record BioXp kit sales, improved gross margins, and significant reductions in operating expenses.

Telesis Bio announced preliminary unaudited financial results for Q4 and full-year 2023, highlighting record BioXp kit sales, increased gross margins, and reduced operating expenses.